Pharmacogenetics

Pharmacogenetics

Warfarin is the treatment of choice in the management of venous thromboembolic disease. The wide interindividual variability in warfarin response is influenced by some genetic variants: in particular, a single nucleotide polymorphism (SNP) in the Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1) known as VKORC1 (1639G>A) that is an important determinant of the initial Warfarin dosage, and two SNPs found in the cytochrome P450 enzyme gene CYP2C9 known as CYP2C9*2 (C430T) and CYP2C9*3 (A1075C).

Pharmacogenetics
ProductCodeCE MarkDescription
VKORC1EER054050EER054050

50 Tests - 1639 G>A

Available for QiaSymphony SP/AS - Ref: EER54032QS

DUPLICA RealTime HLA-B*5701 EZ Type KitEER052032EER052032

32 Tests

CYP2C9*2EER055050EER055050

50 Tests - 430 C>T 

Available for QiaSymphony SP/AS - Ref: EER055032QS

CYP2C9*3EER056050EER056050

50 Tests - 1075 A>C

Available for QiaSymphony SP/AS - Ref: EER056032QS